Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.
Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia. Previously described approaches to blocking myostatin signaling include injection delivery of inhibitory propeptide domain or neut...
Main Authors: | Kevin J Morine, Lawrence T Bish, Klara Pendrak, Meg M Sleeper, Elisabeth R Barton, H Lee Sweeney |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-02-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2820101?pdf=render |
Similar Items
-
Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model.
by: Lawrence T Bish, et al.
Published: (2010-04-01) -
Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.
by: Lawrence T Bish, et al.
Published: (2011-01-01) -
Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse.
by: Joshua T Selsby, et al.
Published: (2012-01-01) -
Erythropoietin reduces the expression of myostatin in mdx dystrophic mice
by: D. Feder, et al.
Published: (2014-11-01) -
Inhibiting Myostatin with Follistatin Improves the Success of Myoblast Transplantation in Dystrophic Mice
by: Basma F. Benabdallah, et al.
Published: (2008-03-01)